Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
NewAmsterdam Pharma Company ( (NAMS) ) has provided an announcement.
NewAmsterdam Pharma reported significant achievements in 2024 with positive results from three pivotal Phase 3 trials for obicetrapib, aimed at lowering LDL-C and reducing cardiovascular risks. The company plans to further advance its clinical trials in 2025 and focus on commercial readiness for potential launches in the U.S. and Europe, supported by a strong financial position.
More about NewAmsterdam Pharma Company
NewAmsterdam Pharma Company N.V. is a late-stage clinical biopharmaceutical company focused on developing oral, non-statin medicines for patients with cardiovascular diseases who have elevated LDL-C levels and for whom existing therapies are ineffective or not well tolerated. The company is advancing obicetrapib, a CETP inhibitor, as a preferred LDL-C lowering therapy, either alone or in combination with ezetimibe.
YTD Price Performance: -1.58%
Average Trading Volume: 784,405
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $2.73B
Learn more about NAMS stock on TipRanks’ Stock Analysis page.
